The DOI matches its Crossref record.
Therapeutic Responses to Different Antimalarial Drugs in Vivax Malaria
Open accessAbstract
The therapeutic responses to the eight most widely used antimalarial drugs were assessed in 207 adult patients with Plasmodium vivax malaria. This parasite does not cause marked sequestration, so parasite clearance can be used as a direct measure of antimalarial activity. The activities of these drugs in descending order were artesunate, artemether, chloroquine, mefloquine, quinine, halofantrine, primaquine, and pyrimethamine-sulfadoxine (PS). Therapeutic responses to PS were poor; parasitemias did not clear in 5 of the 12 PS-treated patients, whereas all the other patients made an initial recovery. Of 166 patients monitored for ≥28 days, 35% had reappearance of vivax malaria 11 to 65 days later and 7% developed falciparum malaria 5 to 21 days after the start of treatment. There were no significant differences in the times taken for vivax malaria reappearance among the different groups except for those given mefloquine and chloroquine, in which all vivax malaria reappearances developed >28 days after treatment, suggesting suppression of the first relapse by these slowly eliminated drugs. There was no evidence of chloroquine resistance. The antimalarial drugs vary considerably in their intrinsic activities and stage specificities of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vivax Malaria: Neglected and Not Benign
Price, R. N., Tjitra, E., Guerra, C. A., Yeung, S., White, N. J., & Anstey, N. M. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.79 · Cited by 838
Self-citationBousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Determinants of relapse periodicity in Plasmodium vivax malaria
White, N. J. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-297 · Cited by 679
Self-citationArtemisinin-Based Combination Treatment of Falciparum Malaria
Nosten, F., & White, N. J. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.181 · Cited by 673
Self-citationAntimalarial Drug Toxicity: A Review
Taylor, W. R. J., & White, N. J. (2004) · Drug Safety · doi:10.2165/00002018-200427010-00003 · Cited by 482
Self-citationWHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
Relapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites
Imwong, M., Snounou, G., Pukrittayakamee, S., Tanomsing, N., Kim, J. R., Nandy, A., Guthmann, J., Nosten, F., Carlton, J., Looareesuwan, S., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/512241 · Cited by 294
Self-citationArtemisinin-based combination therapy for treating uncomplicated malaria
Sinclair, D., Zani, B., Donegan, S., Olliaro, P., & Garner, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007483.pub2 · Cited by 286
UK malaria treatment guidelines
Lalloo, D. G., Shingadia, D., Pasvol, G., Chiodini, P. L., Whitty, C. J., Beeching, N. J., Hill, D. R., Warrell, D. A., & Bannister, B. A. (2007) · Journal of Infection · doi:10.1016/j.jinf.2006.12.003 · Cited by 272
Resistance to Therapies for Infection by Plasmodium vivax
Baird, J. K. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-09 · Cited by 262
White, N. J. (2017) · Malaria Journal · doi:10.1186/s12936-017-1731-1 · Cited by 230
“The most rapid rates are seen following the start of treatment with the artemisinin derivatives and the spiroindolones [23, 28, 29].”
BackgroundSelf-citationDouglas, N. M., Nosten, F., Ashley, E. A., Phaiphun, L., van Vugt, M., Singhasivanon, P., White, N. J., & Price, R. N. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq249 · Cited by 145
Self-citationThanapongpichat, S., McGready, R., Luxemburger, C., Day, N. P., White, N. J., Nosten, F., Snounou, G., & Imwong, M. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-275 · Cited by 32
“1Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.”
BackgroundSelf-citationRadical Cure: The Case for Anti-Relapse Therapy Against All Malarias
Baird, J. K. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq258 · Cited by 12
“In Thailand, 60% of patients treated for acute vivax malaria with rapidly excreted blood schizontocides experienced relapse within 28 days after patency [5].”
Background
Metadata
- Authors
- Pukrittayakamee, S., Chantra, A., Simpson, J. A., Vanijanonta, S., Clemens, R., Looareesuwan, S., & White, N. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-06
- Volume
- 44
- Issue
- 6
- Pages
- 1680-1685
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2048350387
- Cited by
- 174
- References
- 0
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.